title: Prostaglandin E2 binding peptide: a potential modulatory agent which acts through suppressing NF-kappaB signaling in RA.
abstract: In an earlier study, we found PBP inhibited the progress of adjuvant-induced arthritis (AA). This study was aimed at evaluating the inhibitory effects of PBP in terms of NF-κB activation by using immunohistochemical and immunofluorescent technique in vitro and in vivo. IL-1β and TNF-α in serum were detected by method of ELISA. Immunofluorescent results showed that PBP inhibited NF-κB p65 translocation into nucleus. In vivo imaging showed that treatment with PBP decreased the enzyme labeling signal of NF-κB p65. Immunohistochemical staining revealed that PBP suppressed production of NF-κB p65 subunit in the joints and attenuated the productions of IL-1β and TNF-α in serum from AA. Moreover, NF-κB p65 nucleus translocation was prevented by simultaneous incubation with PBP and PGE2 was decreased by PBP through a feedback cycle. We report the first confirmation of the mimotope of PGE2 receptor EP4 modulatory action.
authors.affiliation: Department of Immunology, Norman Bethune College of Medicine, Jilin University, Changchun, China.
authors.forename: Dongmei
authors.initials: D
authors.lastname: Yan
authors.forename: Weihai
authors.initials: W
authors.lastname: Peng
authors.forename: Xiangfeng
authors.initials: X
authors.lastname: Zhao
authors.forename: Xiao
authors.initials: X
authors.lastname: Han
authors.forename: Qihui
authors.initials: Q
authors.lastname: Liu
authors.forename: Peng
authors.initials: P
authors.lastname: Li
authors.forename: Bairong
authors.initials: B
authors.lastname: Du
authors.forename: Xun
authors.initials: X
authors.lastname: Zhu
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D001169:Arthritis, Experimental / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D002478:Cells, Cultured; D015232:Dinoprostone / Q000378:metabolism*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008297:Male; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010446:Peptide Fragments / Q000378:metabolism* / Q000494:pharmacology* / Q000627:therapeutic use; D011485:Protein Binding; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000893:Anti-Inflammatory Agents; D016328:NF-kappa B; D010446:Peptide Fragments; D015232:Dinoprostone